

## **Berwyn Clarke – Chief Scientific Officer**



Dr Berwyn Clarke was the founder and CEO of Oneida TheraDiagnostics Ltd and has been involved in the pharmaceutical industry for the past 24 years. Dr Clarke was Global Director of the hepatitis C virus therapeutic area at GlaxoWellcome between 1990 and 2000 and had previously held management positions within Wellcome Biotechnology and the Wellcome Foundation. In 2000 he moved into the molecular diagnostic industry with Virco UK and, following a series of M&A activities was promoted to Vice President for Research at Visible Genetics Inc. (VGI) a pioneering company in the use of molecular diagnostics for viral and cancer disease management. In 2002 VGI was acquired by Bayer Diagnostics and he became European Director for Scientific Affairs, a role he pursued until his decision to launch Oneida in May 2003. He has been significantly involved in a wide-range of corporate activities and, while proceeding with the successful search for VC investment in Oneida, pursued a number of consultancy projects for both the government and the biotech sector. He also completed a 6-month appointment as interim CEO of Replizyme Ltd., a York based company prior to the integration of Oneida into Lab21 Ltd. As a co-founder of Lab21 Dr Clarke is currently Chief Scientific Officer with additional responsibility for Business Development.